Open AccessClinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma
Author(s) -
Chee Khoon Lee,
Johnathan Man,
Sarah J. Lord,
Wendy A. Cooper,
Matthew Links,
Val Gebski,
Roy S. Herbst,
Richard J. Gralla,
Tony Mok,
James ChihHsin Yang
Publication year - 2017
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2017.4427
Subject(s) - medicine , atezolizumab , docetaxel , nivolumab , oncology , pembrolizumab , hazard ratio , lung cancer , population , randomized controlled trial , chemotherapy , cancer , confidence interval , immunotherapy , environmental health
Checkpoint inhibitors have replaced docetaxel as the new standard second-line therapy in advanced non-small cell lung carcinoma (NSCLC), but little is known about the potential predictive value of clinical and molecular characteristics.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom